Delivery Order SPE2DB22D1200-SPE2DB25FN3PP
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, to provide IMBRUVICA 420 mg tablets. The $43,936.02 order falls under an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen holds with DLA to deliver a wide range of pharmaceuticals and medical supplies to support military treatment facilities worldwide. This order does not have a...
- The Defense Logistics Agency awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count packaging) under a firm fixed price contract type. The delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, carries no set-aside designation, indicating it was awarded through open competition. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count package), with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed from the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (quantity 28) under a firm fixed-price contract. The order, valued at $7,575.75, was competitively awarded without a set-aside designation and is scheduled for completion by August 8, 2025. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Imbruvica 70 mg capsules (28-count units) with a contract value of $7,575.75. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside designation, and the place of performance is...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $15,151.52 for IMBRUVICA 280mg 28-count tablets under a firm fixed-price contract with the Defense Logistics Agency Medical Supply Chain. The award, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-set-aside competitive award. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of IMBRUVICA 420 mg tablets to support military and government healthcare programs. The $7,575.75 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 13, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $16,233.74 for IMBRUVICA 140 mg capsules (90-count units) under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 28, 2025, with an ultimate completion date of August 18, 2025, and represents a non-set-aside, competitively awarded contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,467.48 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 140 mg capsules (90-count units). This firm fixed-price, competitively awarded delivery order carries an ultimate completion date of August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside procurement, demonstrating AmerisourceBergen's continued capability to...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide IMBRUVICA 280 MG TABLET 28S. The contract has a potential value of $7,322.67 and a completion date of March 4, 2024. This delivery order is issued under an existing indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, with a potential value of up to $999,999,999.00 and a performance period...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN3PPDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) with delivery to Conshohocken, Pennsylvania. This contract, awarded on August 4, 2025, utilizes a firm fixed-price structure with an ultimate completion date of August 25, 2025. The award was made without a set-aside designation, indicating it was competitively awarded among qualified vendors. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills a critical role in the federal medical supply chain, particularly supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a wide range of pharmaceutical products and medical supplies through the DLA Troop Support Medical program. IMBRUVICA (ibrutinib) is a targeted cancer therapy, indicating this procurement supports military medical readiness and treatment capabilities for service members and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/4/25 |